Triazole antifungal agents drugdrug interactions involving hepatic cytochrome P450

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 11, 2011, Pages 1411-1429

  Gubbins, Paul O ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

CYP; CYP polymorphisms; Drug metabolism; Fluconazole; Itraconazole; Posaconazole; Triazole antifungals; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUDESONIDE; BUSPIRONE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DEXAMETHASONE; FLUCONAZOLE; FLUTICASONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; METHYLPREDNISOLONE; MIDAZOLAM; POSACONAZOLE; RAPAMYCIN; TACROLIMUS; TRIAZOLAM; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ACCURACY; ADRENAL INSUFFICIENCY; ANALYTIC METHOD; AREA UNDER THE CURVE; CUSHING SYNDROME; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG TRANSFORMATION; FIRST PASS EFFECT; GENOTYPE; HUMAN; LIVER TOXICITY; NEPHROTOXICITY; PHARMACOGENETICS; REVIEW; STEREOCHEMISTRY; TECHNOLOGY;

ANTIFUNGAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; MYCOSES; TRIAZOLES;

EID: 80054724621     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.627854     Document Type: Review

References (120)

1. Gubbins PO, Heldenbrand SD. Clinically relevant drug interactions of current antifungal agents. Mycoses 2010;53:95-113
2. Guengerich FP. Cytochrome P450 and chemical toxicology. Chem Res Toxicol 2008;21:70-83 (Pubitemid 351219709)
3. Gubbins PO. Mould active azoles: pharmacokinetics, drug interactions in neutropenic hosts. Curr Opin Infect Dis 2007;20:579-86
4. Gubbins PO, Amsden JR. Drug-drug interactions of antifungal agents and implications for patient care. Expert Opin Pharmacother 2005;6:2231-43 (Pubitemid 41582210)
5. Lamba JK, Lin YS, Thummel K, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002;12:121-32 (Pubitemid 34298916)
6. Daly AK. Significance of minor cytochrome P450 3A isoforms. Clin Pharmacokinet 2006;45:13-31 (Pubitemid 43145013)
7. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91 (Pubitemid 32268418)
8. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999;37:485-505 (Pubitemid 30032252)
9. Isoherranen N, Kunze KL, Allen KE, et al. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 2004;32:1121-31 (Pubitemid 39287586)
10. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003;31:540-7 (Pubitemid 36444162)
11. Roffey SJ, Cole S, Comby P, et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 2003;31:731-41 (Pubitemid 36617661)
12. Murayama N, Imai N, Nakane T, et al. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol 2007;73:2020-6 (Pubitemid 46677908)
13. Weiss J, ten Hovel MM, Burhenne J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 2009;49:196-204
14. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52:349-55 (Pubitemid 32939439)
15. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochome P450 enzymes and its clinical importance. Drug Metab Rev 2009;41:89-295
16. Available from: http://www.imm.ki.se/CYPalleles [Access date 22 January 2011]
17. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006;79:103-13 (Pubitemid 43069582)
18. Li-Wan-Po A, Girard T, Farndon P, et al. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol 2010;69:222-30
19. Wang B, Wang J, Huang SQ, et al. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr Drug Metab 2009;10:781-834
20. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002;12:251-63 (Pubitemid 34596790)
21. Brammer KW, Coakley AJ, Jezequel SG, Tarbit MH. The disposition and metabolism of [14C]fluconazole in humans. Drug Metab Dispos 1991;19:764-7
22. Uko S, Soghier LM, Vega M, et al. Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics 2006;117:1243-52 (Pubitemid 46071518)
23. Locuson CW, Hutzler JM, Tracy TS. Visible spectra of type II cytochrome P450-drug complexes: Evidence that "incomplete" heme coordination is common. Drug Metab Dispos 2007;35:614-22 (Pubitemid 46513265)
24. Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989;32(1 Suppl):67-87
25. Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 1998;35:461-73 (Pubitemid 29010176)
26. Bourcier K, Hyland R, Kempshall S, et al. Investigation into UDP-Glucuronosyltransferase (UGT) Enzyme kinetics of imidazole-and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes. Drug Metab Dispos 2010;38:923-9
27. Templeton IE, Thummel KE, Kharasch ED, et al. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 2008;83:77-85
28. Kunze KL, Nelson WL, Kharasch ED, et al. Stereochemical aspects of itraconazole metabolism in vitro and in vivo. Drug Metab Dispos 2006;34:583-90
29. Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 2009;68:906-15
30. Yanni SB, Annaert PP, Augustijns P, et al. Role of flavin containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos 2008;36:1119-25 (Pubitemid 351717470)
31. Wang G, Lei HP, Li Z, et al. The CYP ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol 2009;65:281-5
32. Lee SH, Kim BH, Nam WS, et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Phamacol 2011; published online 7 March 2011; DOI: 10.1177/0091270010395510
33. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single-or multiple-dose administration. Antimicrob Agents Chemother 2004;48:2166-72 (Pubitemid 38691615)
34. Yanni SB, Annaert PP, Augustijns P, et al. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: Role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos 2010;38:25-31
35. Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004;48:3543-51 (Pubitemid 39129357)
36. Ghosal A, Hapangama N, Yuan Y, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004;32:267-71 (Pubitemid 38176945)
37. Kim H, Lin CC, Laughlin M, et al. Chiral high-performance liquid chromatographic analysis of antifungal SCH 56592 and evaluation of its chiral inversion in animals and humans. Chirality 2000;12:590-7 (Pubitemid 30409549)
38. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430 (Pubitemid 28231501)
39. Gibbs MA, Thummel KE, Shen DD, Kunze KL. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 1999;27:180-7 (Pubitemid 29072069)
40. Isoherranen N, Ludington SR, Givens RC, et al. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate dependent: an in vitro-in vivo evaluation. Drug Metab Dispos 2008;36:146-54
41. Jeong S, Nguyen PD, Desta Z. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: Major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother 2009;53:541-51
42. Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 2005;28:1805-8 (Pubitemid 41324160)
43. Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 2002;46:3091-3
44. Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, 2D6, and 2E1 activities in human liver microsomes. Biol Pharm Bull 2005;28:1813-16 (Pubitemid 41324162)
45. Wexler D, Courtney R, Richards W, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004;21:645-53 (Pubitemid 38447146)
46. Yamazaki H, Nakamoto M, Shimizu M, et al. Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. Br J Clin Pharmacol 2010;69:593-7
47. Templeton I, Peng CC, Thummel KE, et al. CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clin Pharmacol Ther 2010;88:499-505
48. Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996;82:511-16 (Pubitemid 26072953)
49. Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 1998;54:53-8 (Pubitemid 28189400)
50. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 1997;51:415-19 (Pubitemid 27055911)
51. Krishna G, Moton A, Ma L, et al. Effects of oral posaconazole on the pharmacokinetics of oral and intravenous midazoloam: A phase I randomized, open-label, crossover study in healthy volunteers. Clin Ther 2009;31:286-98
52. Varhe A, OLkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-7 (Pubitemid 124006567)
53. Neuvonen PJ, Varhe A, Olkkola KT. The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clin Pharmacol Ther 1996;60:326-31 (Pubitemid 26354453)
54. Varhe A, Olkkola KT, Neuvonen PJ. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 1996;41:319-23 (Pubitemid 26114819)
55. Varhe A, Olkkola KT, Neuvonen PJ. Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br J Clin Pharmacol 1996;42:465-70 (Pubitemid 26340147)
56. Yu KS, Cho JY, Jang IJ, et al. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther 2004;76:104-12
57. Saari TI, Laine K, Leino K, et al. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 2006;79:362-70
58. Jung F, Richardson TH, Raucy JL, Johnson EF. Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low K(M) diazepam N-demethylases. Drug Metab Dispos 1997;25:133-9 (Pubitemid 27086112)
59. Yang TJ, Krausz KW, Sai Y, et al. Eight inhibitory monoclonal antibodies define the role of individual P-450s in human microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Drug Metab Dispos 1999;27:102-9 (Pubitemid 29061008)
60. Saari TI, Laine K, Bertilsson L, et al. Voriconazole and fluconazole increase the exposure to oral diazepam. Eur J Clin Pharmacol 2007;63:941-9 (Pubitemid 47387914)
61. Ahonen J, Olkkola KT, Neuvonen PJ. The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Fundam Clin Pharmacol 1996;10:314-18 (Pubitemid 26228383)
62. Kruger HU, Schuler U, Zimmermann R, et al. Absence of significant interaction of fluconazole with cyclosporin. J Antimicrob Chemother 1989;24:781-6 (Pubitemid 20005509)
63. Canafax DM, Graves NM, Hilligoss DM, et al. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991;51:1014-18
64. Lopez-Gil JA. Fluconazole-cyclosporine interaction: a dose-dependent effect? Ann Pharmacother 1993;27:427-30 (Pubitemid 23123889)
65. Sud K, Baljinder S, Krishna VS, et al. Unpredictable cyclosporine- fluconazole interaction in renal transplant recipients. Nephrol Dial Transplant 1999;14:1698-703 (Pubitemid 29313048)
66. Manez R, Martin M, Raman D, et al. Fluconazole therapy in transplant recipients receiving FK506. Transplantation 1994;57:1521-3
67. Mihara A, Mori T, Yamazaki R, et al. Greater impact of oral fluconazole on drug interaction with intravenous calcineurin inhibitors as compared with intravenous fluconazole. Eur J Clin Pharmacol 2008;64:89-91
68. Leather H, Boyette RM, Tian L, Wingard JR. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006;12:325-34 (Pubitemid 43273718)
69. Billaud EM, Guillemain R, Tacco F, Chevalier P. Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. Br J Clin Pharmacol 1998;46:271-2 (Pubitemid 28404842)
70. Romero AJ, Le Pogamp P, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant recipients. Clin Pharmacol Ther 2002;71:226-34 (Pubitemid 34311451)
71. Mori T, Asia Y, Kato J, et al. Drug interaction between calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2009;44:371-4
72. Venkataramanan R, Zang S, Gayowski T, et al. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 2002;46:3091-3
73. Tintillier M, Kirch L, Goffin E, et al. Interaction between voriconazole and tacrolimus in a kidney-transplanted patient. Nephrol Dial Transplant 2005;20:664-5 (Pubitemid 40378452)
74. Sansone-Parsons A, Krishna G, Martinho M, et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007;27:825-34 (Pubitemid 46849426)
75. Kuypers DR, de Jong H, Naesens M, Vanrenterghem Y. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics 2008;18:861-8
76. Dai Y, Hebert MF, Isoherranen N, et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006;34:836-47
77. Nara M, Takahashi N, Miura M, et al. Effect of itraconazole on the pharmacokinetics of tacrolimus in a hematopoietic stem cell transplant recipient with CYP3A5*3/*3. Am J Hematol 2010;85:634-5
78. Kuypers DR, Claes K, Evenepoel P, et al. Drug interaction between itraconazole and sirolimus in a primary renal allograft recipient. Transplantation 2005;79:737 (Pubitemid 40463185)
79. Said A, Garnick JJ, Dieterle N, et al. Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient. Pharmacotherapy 2006;26:289-95 (Pubitemid 43201879)
80. Cervelli MJ. Fluconazole-sirolimus drug interaction. Transplantation 2002;27:1477-8
81. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006;26:1730-44 (Pubitemid 44885328)
82. Moton A, Ma L, Krishna G, et al. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr Med Res Opin 2009;25:701-7
83. Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther 1998;64:363-8 (Pubitemid 28473761)
84. Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001;51:443-50 (Pubitemid 32852982)
85. Varis T, Kivisto KT, Backman JT, Neuvonen PJ. Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. Pharmacol Toxicol 1999;85:29-32 (Pubitemid 29291191)
86. Varis T, Kivisto KT, Backman JT, Neuvonen PJ. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther 2000;68:487-94
87. Varis T, Kivisto KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol 2000;56:57-60 (Pubitemid 30317782)
88. Raaska K, Niemi M, Neuvonen M, et al. Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. Clin Pharmacol Ther 2002;72:362-9 (Pubitemid 35178862)
89. Naef R, Schmid C, Hofer M, et al. Systemic levels of inhaled fluticasone in lung transplant recipients. Respiration 2007;74:418-22
90. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-81 (Pubitemid 44908269)
91. Kantola T, Backman JT, Niemi M, et al. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000;56:225-9 (Pubitemid 30456682)
92. Cooper KJ, Martin PD, Dane AL, et al. Effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002;58:527-31
93. Shaukat A, Benekli M, Vladutiu GD, et al. Simvastatin-fluconazole causing rhabdomyolysis. Ann Pharmacother 2003;37:1032-5 (Pubitemid 36875235)
94. Hazin R, Abuzetun JY, Suker M, Porter J. Rhabdomyolysis induced by simvastatin-fluconazole combination. J Natl Med Assoc 2008;100:444-6 (Pubitemid 351556507)
95. Kahri J, Valkonen M, Backlund T, et al. Rhabdomyolysis in a patient receiving atorvastatin and fluconazole. Eur J Clin Pharmacol 2005;60:905-7 (Pubitemid 40386163)
96. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60:54-61 (Pubitemid 26279221)
97. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-41 (Pubitemid 28182231)
98. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998;64:58-65 (Pubitemid 28377331)
99. Mazzu AL, Lasseter KC, Shamblin EC, et al. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000;68:391-400
100. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998;46:49-53 (Pubitemid 28308424)
101. Ishigam M, Uchiyama M, Kondo T, et al. Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and predictions of in vivo drug-drug interactions. Pharm Res 2001;18:622-31 (Pubitemid 32595790)
102. Cooper KJ, Martin PD, Dane AL, et al. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2003;73:322-9 (Pubitemid 36403592)
103. Kim KA, Park PW, Lee OJ, et al. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol 2007;47:87-93
104. Bonay M, Jonville-Bera AP, Diot P, et al. Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Saf 1993;9:309-11 (Pubitemid 23302156)
105. Ducharme MP, Slaughter RL, Warbasse LH, et al. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin Pharmacol Ther 1995;58:617-24 (Pubitemid 26018847)
106. Jaruratanasirikul S, Sriwiriyajan S. Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. Eur J Clin Pharmacol 1998;54:155-8 (Pubitemid 28204269)
107. Jaruratanasirikul S, Sriwiriyajan S. Pharmacokinetic study of the interaction between itraconazole and nevirapine. Eur J Clin Pharmacol 2007;63:451-6 (Pubitemid 46569924)
108. Blum RA, Wilton JH, Hilligoss DM, et al. Effect of fluconazole on disposition of phenytoin. Clin Pharmacol Ther 1991;49:420-5
109. Apseloff G, Hilligoss DM, Gardner MJ, et al. Induction of fluconazole metabolism by rifampin: in vivo study in humans. J Clin Pharmacol 1991;31:358-61
110. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-7 (Pubitemid 36259570)
111. Nagappan V, Deresinski S. Posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007;45:1610-17 (Pubitemid 351411847)
112. Muijser RBR, Goa KL, Scott LJ. Voriconazole in the treatment of invasive aspergillosis. Drugs 2002;18:2655-64
113. Purkins L, Wood N Ghahramani P, et al. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol 2003;56(Suppl 1):37-44 (Pubitemid 37491732)
114. Mikus G, Schowel V, Drzewinska M, et al. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006;80:126-35 (Pubitemid 44160688)
115. Liu P, Grover F, Gandelman K, et al. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother 2007;51:3617-26 (Pubitemid 47519352)
116. Liu P, Foster G, Labadie RR, et al. Voriconazole and efavirenz at steady state n healthy male subjects. J Clin Pharmacol 2008;48:73-84
117. Damle B, LaBadie R, Crownover P, Glue P. Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. Br J Clin Pharmacol 2008;65:523-30 (Pubitemid 351365141)
118. Krishna G, Moton A, Ma L, et al. Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers. J Acquir Immune Defic Syndr 2009;51:437-44
119. Krishna G, Sansone-Parsons A, Kantesaria B. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men. Curr Med Res Opin 2007;23:1415-22 (Pubitemid 46998449)
120. Krishna G, Parsons A, Kantesaria B, Mant T. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin 2007;23:545-52 (Pubitemid 46456902)